These findings reinforce the notion of the efficacy of Ibrutinib in B-CLL carrying TP53 mutations [18, 19], and provide the first evidence concerning the ability of Ibrutinib to target the TP53mut clones. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.